dolutegravir; lamivudine; tenofovir disoproxil fumarate
DOLUTEGRAVIR, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE (dolutegravir; lamivudine; tenofovir disoproxil fumarate) by Shanghai Sunway Biotech is fixed-dose combination of the hiv‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see microbiology ()]. Approved for hiv-1 infection in adults, weighing at least 6 kg.
Drug data last refreshed 13h ago · AI intelligence enriched 1mo ago
A fixed-dose combination tablet containing dolutegravir (integrase strand transfer inhibitor), lamivudine (nucleoside reverse transcriptase inhibitor), and tenofovir disoproxil fumarate (nucleotide reverse transcriptase inhibitor) for treatment of HIV-1 infection. This three-drug oral regimen targets multiple steps of HIV replication to suppress viral load in treatment-naive and treatment-experienced adults and pediatric patients weighing at least 6 kg.
Early-stage product in pre-launch phase with limited commercial infrastructure; hiring focused on launch planning, regulatory affairs, and market access functions.
fixed-dose combination of the HIV‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see Microbiology ()].
Worked on DOLUTEGRAVIR, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE at Shanghai Sunway Biotech? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on this product offers early-stage launch experience in a crowded HIV market with significant focus on pricing, reimbursement strategy, and competitive positioning. Career growth depends on ability to differentiate a commodity-like product and execute in resource-limited and emerging markets where fixed-dose combinations have highest impact.